Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children - Zhang, Qing; Zhou, Chun‐Ju; Li, Dan‐Hong; Cui, Lei; Li, Wei‐Jing; Ma, Hong‐Hao; Zhao, Yun‐Ze; Wang, Dong; Li, Zhi‐Gang; Wang, Tian‐You; Wei, Li; Duan, Yan‐Long; et al. (British journal of haematology, 2023)
Keywords: Chemotherapy; Child; Child, Preschool; Corticosteroids; Germ-Line Mutation; HAVCR2 mutation; Hematology; hemophagocytic lymphohistiocytosis; Hepatitis A Virus Cellular Receptor 2 - genetics; Histiocytosis; Humans; Immunosuppressive agents; Infant; Lymphocytosis; Lymphohistiocytosis, Hemophagocytic - complications; Lymphohistiocytosis, Hemophagocytic - drug therapy; Lymphohistiocytosis, Hemophagocytic - genetics; Lymphoma; Mutation; Panniculitis - drug therapy; Panniculitis - genetics; Patients; Remission; ruxolitinib; Skin diseases; Skin lesions; subcutaneous T‐cell lymphoma; subcutaneous T-cell lymphoma; hemophagocytic lymphohistiocytosis; HAVCR2 mutation; ruxolitinib